Re: Farmas USA
KERX
American billionaire Seth Klarman is the founder of the Baupost Group, the world’s 11th largest hedge fund. Klarman’s portfolio is valued at $6 billion. In the last three years, his portfolio has achieved an annualized return of 7.71%. Here are some of his hedge fund’s recent transactions:
In the most recent quarter, Klarman added Keryx Biopharmaceuticals (NASDAQ:KERX) to his portfolio, increasing his stake in Keryx by 15.24%. He holds $89.5 million worth of shares, comprising about 1.5% of his entire holdings. The drug developer, which focuses on the treatment of renal disease, recently announced the official approval of its drug Fexeric by the European commission. Fexeric is useful for controlling the levels of serum phosphorous in patients with chronic kidney disease. As per TipRanks, out of 8 analysts who have recently rated the stock, 3 have rated it as a Buy and 4 have given it a Hold rating. Only 1 analyst has given a Sell rating to Keryx. The average consensus price target for the stock is $9.50, an upside of nearly 156% from current levels.
Re: Farmas USA
Jejeje,,,,,,,veremos,no son para hoy ni para mañana.
A ver si las calientan
La unica analista de la que me fio y sigo es .....la portera de mi casa.
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
Pues claro que estara.
Re: Farmas USA
KERX
En Agosto compraron algo
http://openinsider.com/search?q=kerx